Tin tức & Cập nhật
Xem bài viết Ung thư
Xem
SWOG S1616 suggests PFS benefit with ipi-nivo combo in metastatic/unresectable melanoma
The combination of ipilimumab and nivolumab may provide a progression-free survival (PFS) benefit in patients with metastatic or unresectable melanoma who did not respond to anti-PD-1/anti-PD-L1 therapy, according to a small study presented at AACR 2022.
Short-term ADT leads to worse survival in prostate cancer patients on IMRT
Short-term concurrent androgen deprivation therapy (ADT) results in markedly worse overall survival (OS) among intermediate-risk (IR) prostate cancer patients on dose-escalated intensity modulated radiation therapy (IMRT) with daily image-guided RT, reveals a study.
Sotorasib demonstrates durable efficacy in KRASG12C-mutated NSCLC
The KRASG12C inhibitor sotorasib has demonstrated durable efficacy in patients with locally advanced or metastatic KRASG12C-mutated non-small-cell lung cancer (NSCLC), with 2-year overall survival (OS) reported in one-third of patients in the CodeBreaK 100 trial.
Adding canakinumab to SoC confers no survival benefit in advanced NSCLC
The addition of the monoclonal anti-interleukin-1β antibody canakinumab to the standard of care (SoC) regimen of platinum doublet chemotherapy and pembrolizumab in the first-line setting did not improve progression-free survival (PFS) or overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC), results of the phase III CANOPY-1 trial showed.
Trabectedin–durvalumab combo shows antitumour activity in refractory ovarian carcinoma
Combination treatment with trabectedin and durvalumab appears to be promising in the treatment of patients with platinum-refractory ovarian carcinoma, shrinking tumour while having a manageable side effect profile, according to data from the phase Ib TRAMUNE trial.
